Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.

Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A.

J Exp Med. 2013 Nov 18;210(12):2627-39. doi: 10.1084/jem.20131144. Epub 2013 Nov 11.

2.

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.

Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, Iwama A.

Blood. 2015 Sep 3;126(10):1172-83. doi: 10.1182/blood-2015-03-634428. Epub 2015 Jul 28.

3.

[An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].

Wang JY, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1303-9. Review. Chinese.

PMID:
22040993
4.

Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.

Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A.

Leukemia. 2017 Apr;31(4):861-871. doi: 10.1038/leu.2016.268. Epub 2016 Oct 3.

PMID:
27694924
5.

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave LM, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL.

J Exp Med. 2013 Nov 18;210(12):2641-59. doi: 10.1084/jem.20131141. Epub 2013 Nov 11.

6.

TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.

Wang J, Ai X, Gale RP, Xu Z, Qin T, Fang L, Zhang H, Pan L, Hu N, Zhang Y, Xiao Z.

Leuk Res. 2013 Mar;37(3):305-11. doi: 10.1016/j.leukres.2012.10.004. Epub 2012 Oct 23.

PMID:
23099237
7.

Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.

Sashida G, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto T, Hayashi Y, Suzuki K, Nakajima H, Inaba T, Koseki H, Huang G, Kitamura T, Iwama A.

Nat Commun. 2014 Jun 23;5:4177. doi: 10.1038/ncomms5177.

PMID:
24953053
8.

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP.

Blood. 2009 Jun 18;113(25):6403-10. doi: 10.1182/blood-2009-02-205690. Epub 2009 Apr 16.

9.

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C, Doubek M, Steurer M, Tosic N, Pavlovic S, Guglielmelli P, Pieri L, Vannucchi AM, Gisslinger H, Cazzola M, Kralovics R.

Am J Hematol. 2012 Mar;87(3):245-50. doi: 10.1002/ajh.22257. Epub 2011 Dec 21.

10.

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.

Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, Zhang Z, He Q, Chang C.

Ann Hematol. 2011 Jun;90(6):643-53. doi: 10.1007/s00277-010-1128-5. Epub 2010 Dec 2.

PMID:
21125401
11.

Mutation in TET2 in myeloid cancers.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA.

N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.

12.

The role of mutations in epigenetic regulators in myeloid malignancies.

Shih AH, Abdel-Wahab O, Patel JP, Levine RL.

Nat Rev Cancer. 2012 Sep;12(9):599-612. doi: 10.1038/nrc3343. Epub 2012 Aug 17. Review.

PMID:
22898539
13.

Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.

Mochizuki-Kashio M, Mishima Y, Miyagi S, Negishi M, Saraya A, Konuma T, Shinga J, Koseki H, Iwama A.

Blood. 2011 Dec 15;118(25):6553-61. doi: 10.1182/blood-2011-03-340554. Epub 2011 Oct 31. Erratum in: Blood. 2012 Jul 26;120(4):924.

14.

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH.

Nat Genet. 2010 Aug;42(8):665-7. doi: 10.1038/ng.620. Epub 2010 Jul 4.

PMID:
20601954
15.

Activating CBL mutations are associated with a distinct MDS/MPN phenotype.

Schwaab J, Ernst T, Erben P, Rinke J, Schnittger S, Ströbel P, Metzgeroth G, Mossner M, Haferlach T, Cross NC, Hochhaus A, Hofmann WK, Reiter A.

Ann Hematol. 2012 Nov;91(11):1713-20. doi: 10.1007/s00277-012-1521-3. Epub 2012 Aug 10.

PMID:
23010802
16.

Genetics of the myeloproliferative neoplasms.

Abdel-Wahab O.

Curr Opin Hematol. 2011 Mar;18(2):117-23. doi: 10.1097/MOH.0b013e328343998e. Review.

PMID:
21307773
17.

Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes.

Oguro H, Yuan J, Tanaka S, Miyagi S, Mochizuki-Kashio M, Ichikawa H, Yamazaki S, Koseki H, Nakauchi H, Iwama A.

J Exp Med. 2012 Mar 12;209(3):445-54. doi: 10.1084/jem.20111709. Epub 2012 Feb 20.

18.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901. Epub 2006 Aug 15.

PMID:
16963837
19.

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.

Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A.

Nature. 2010 Dec 9;468(7325):839-43. doi: 10.1038/nature09586.

20.

New mutations and pathogenesis of myeloproliferative neoplasms.

Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA.

Blood. 2011 Aug 18;118(7):1723-35. doi: 10.1182/blood-2011-02-292102. Epub 2011 Jun 7. Review.

Supplemental Content

Support Center